CD138 targeting with a mAb coupled to a radionuclide emitting alpha particles also represents a potential new therapeutic option for MM and the use of alpha emitters with longer half-lives, such as 211At (7.2 h), should be evaluated in the clinic. This evidence concerns the gene SDC1 and Miyoshi myopathy.